Cardiovascular disease quietly claims more women's lives than breast cancer, lung cancer, and chronic obstructive pulmonary disease combined — yet a persistent awareness gap among both patients and clinicians continues to delay diagnosis and treatment. This mismatch between epidemiological reality and clinical attention may be costing women decades of healthy life.
A comprehensive review published in the European Heart Journal maps both traditional and sex-specific cardiovascular risk factors in women, highlighting where evidence is weakest and intervention most urgently needed. The analysis draws particular attention to physiological differences in the coronary vasculature — including microvascular dysfunction and non-obstructive coronary artery disease patterns — that are more prevalent in women and frequently missed by diagnostic protocols designed around male presentations. The review also examines how risk-enhancing factors unique to women, including adverse pregnancy outcomes, premature menopause, polycystic ovary syndrome, and autoimmune conditions, interact with traditional risk markers such as hypertension, dyslipidemia, and diabetes. Critically, the authors argue that the pre-menopausal period — long assumed to be cardioprotective — is not a risk-free window but rather the earliest window for detecting subclinical disease, with sex-specific thresholds for standard biomarkers warranting recalibration.
This review lands at a meaningful inflection point in cardiovascular medicine. Decades of clinical trials systematically under-enrolled women, leaving sex-disaggregated data sparse and sex-specific treatment thresholds poorly validated. The authors' emphasis on a lifelong care model — tracking cardiovascular trajectory across reproductive milestones rather than initiating risk assessment only post-menopause — aligns with an emerging evidence base in preventive cardiology. The limitation here is inherent to a review format: it synthesizes existing knowledge and identifies gaps rather than generating new empirical data. Still, its publication in a leading cardiology journal signals institutional recognition that female-specific cardiovascular biology is no longer a niche concern. For health-conscious adults, the practical implication is population-level: current screening paradigms may systematically underestimate risk in women below 55, and that blind spot deserves scrutiny from both clinicians and patients alike.